Last updated: October 5, 2026
Iberdomide hydrochloride, also known as iberdomide or CC-220, is an investigational oral cereblon E3 ligase modulator owned by Bristol Myers Squibb through its acquisition of Celgene. It has no FDA-approved indication, no commercial revenue, and no Orange Book listing. Its value depends on Phase 3 execution in relapsed or refractory multiple myeloma and on whether it can differentiate from generic immunomodulatory drugs, newer CELMoD agents, bispecific antibodies and CAR-T therapies.
The commercial opportunity is potentially significant because iberdomide is designed for patients whose disease has become resistant to lenalidomide and pomalidomide. The main financial risk is that the same treatment setting is rapidly shifting toward antibody-based combinations, bispecific T-cell engagers and cellular therapies.
What is iberdomide hydrochloride and how does it work?
Iberdomide is an oral cereblon E3 ligase modulator, or CELMoD, derived from Celgene’s immunomodulatory drug platform. It binds cereblon and alters the ubiquitination and degradation of selected proteins, producing direct anti-myeloma activity and immune stimulation.
The drug is being developed primarily for multiple myeloma, especially patients with disease exposed or refractory to the three major classes used in modern treatment:
- Immunomodulatory drugs such as lenalidomide and pomalidomide
- Proteasome inhibitors such as bortezomib and carfilzomib
- Anti-CD38 antibodies such as daratumumab and isatuximab
This population has a high unmet need, but it also has a limited treatment duration and substantial competition from newer therapies.
What is the development code for iberdomide?
Iberdomide was developed as CC-220 by Celgene. Bristol Myers Squibb became the sponsor after acquiring Celgene in 2019 in a transaction valued at approximately $74 billion, including assumed debt (Bristol Myers Squibb, 2019).
What is the difference between iberdomide and mezigdomide?
Both drugs are next-generation CELMoD agents originating from the Celgene platform. Iberdomide is being developed mainly for multiple myeloma, while mezigdomide, formerly CC-92480, has also been studied extensively in heavily pretreated multiple myeloma.
The commercial positioning is therefore linked to portfolio strategy. BMS must decide whether the two assets will occupy different treatment lines or compete within the same relapsed/refractory population.
| Attribute |
Iberdomide |
Mezigdomide |
| Developer |
Bristol Myers Squibb |
Bristol Myers Squibb |
| Origin |
Celgene CC-220 |
Celgene CC-92480 |
| Modality |
Oral CELMoD |
Oral CELMoD |
| Primary disease focus |
Multiple myeloma |
Multiple myeloma |
| Commercial status |
Investigational |
Investigational in key myeloma settings |
| Strategic role |
Potential post-IMiD therapy |
Potential high-activity salvage therapy |
What is the FDA regulatory status of iberdomide?
Iberdomide has not received FDA approval based on publicly available disclosures through June 2024. It therefore has no approved label, no FDA-recognized commercial indication and no marketed product revenue.
Bristol Myers Squibb has evaluated iberdomide in multiple myeloma clinical trials, including combinations with dexamethasone and other standard agents. The principal regulatory path would likely require a positive randomized Phase 3 result in a defined relapsed or refractory population, followed by a New Drug Application.
Does iberdomide have Breakthrough Therapy Designation?
Bristol Myers Squibb has reported regulatory engagement for iberdomide in heavily pretreated multiple myeloma. Public company disclosures and clinical-development materials should be treated as the controlling record for the status of any Breakthrough Therapy, Fast Track or other FDA designation because designations can apply to specific indications and may change during development.
A regulatory designation would accelerate interaction with the FDA but would not guarantee approval or eliminate the requirement for adequate and well-controlled clinical evidence.
When could iberdomide reach the market?
No confirmed FDA approval date or launch date has been publicly established. Commercial entry depends on several milestones:
| Milestone |
Commercial implication |
| Completion of Phase 3 studies |
Determines whether the asset has registrational evidence |
| Readout in triple-class-exposed disease |
Tests activity in the highest unmet-need segment |
| FDA submission |
Establishes the formal regulatory review timetable |
| FDA approval |
Creates the first potential product revenue |
| Reimbursement and guideline adoption |
Determines real-world uptake |
| Combination-label expansion |
Increases addressable patient population |
The most plausible initial launch setting would be late-line or triple-class-exposed multiple myeloma. Earlier-line use would offer a larger market but require stronger comparative evidence against established combinations.
What clinical factors will determine iberdomide’s market value?
The central commercial question is whether iberdomide can provide clinically meaningful benefit after lenalidomide and pomalidomide failure without losing the convenience and manufacturing advantages of an oral drug.
Key value drivers include:
- Overall response rate and duration of response in triple-class-exposed patients.
- Progression-free survival compared with pomalidomide-based or physician-choice regimens.
- Activity in patients refractory to prior CELMoD treatment.
- Compatibility with daratumumab, carfilzomib, bortezomib and dexamethasone.
- Oral dosing convenience compared with injectable antibodies, bispecifics and CAR-T.
- Hematologic toxicity, infection risk and treatment discontinuation.
- Ability to move into earlier lines of therapy.
The most important comparator is not lenalidomide, which is largely generic, but the growing group of active treatments for advanced disease. These include bispecific antibodies such as teclistamab, elranatamab and talquetamab, CAR-T products such as idecabtagene vicleucel and ciltacabtagene autoleucel, and antibody-drug conjugates or next-generation combinations under development.
How large is the potential market for iberdomide?
Iberdomide’s addressable population is smaller than the total multiple myeloma market because the likely first indication would target patients with multiple prior therapies. The opportunity could expand materially if the drug proves effective in earlier relapsed disease or in combination regimens.
The market has four economic characteristics:
- Multiple myeloma is a chronic, treatment-intensive cancer with repeated lines of therapy.
- Late-line patients have high medical need but shorter treatment duration.
- Oral therapy can reduce infusion-center utilization and improve convenience.
- Payers may demand evidence of superiority or meaningful differentiation because many competing products are available.
A late-line product can generate substantial revenue if it achieves rapid uptake across the United States, Europe and Japan. It is less likely to reach blockbuster scale without label expansion into earlier-line treatment or broad combination use.
What is iberdomide’s financial trajectory?
Iberdomide currently generates no product sales because it is not approved. Bristol Myers Squibb does not separately report iberdomide revenue, operating profit or development spending in its public financial statements. Clinical costs are included within broader research and development expenses.
Financial trajectory by development stage
| Stage |
Revenue profile |
Main financial exposure |
| Pre-approval development |
Zero product revenue |
Phase 3, manufacturing and regulatory costs |
| Regulatory submission |
Zero product revenue |
Filing, launch preparation and market-access investment |
| Initial approval |
Initial launch revenue |
Pricing, reimbursement and commercial execution |
| Late-line adoption |
Moderate potential revenue |
Competition from bispecifics and CAR-T |
| Earlier-line expansion |
Higher revenue potential |
Comparative trials and combination development |
| Failure or delay |
No revenue |
Write-down risk and stranded development spending |
The asset’s near-term financial impact is therefore negative or neutral rather than revenue-generating. Its valuation is based on probability-adjusted future cash flow, not current sales.
How could iberdomide affect Bristol Myers Squibb revenue?
Bristol Myers Squibb faces long-term portfolio pressure from the loss of exclusivity for major products, including Revlimid, Eliquis and Opdivo in different jurisdictions and at different times. A successful iberdomide launch could support the company’s hematology franchise, but it would need to replace only a fraction of the revenue associated with mature products.
The most valuable scenario would combine:
- Approval in triple-class-exposed multiple myeloma.
- A favorable oral-treatment profile.
- Use with dexamethasone and anti-CD38 therapy.
- Expansion into earlier relapsed disease.
- Adoption before patients progress to cellular therapy or bispecific treatment.
The weaker scenario would involve approval only in a narrow salvage population, modest response durability and intense competition from off-the-shelf bispecific antibodies. That outcome could support a specialty product but would limit revenue scale.
What patents protect iberdomide hydrochloride?
Iberdomide is protected through a patent estate originating with Celgene and transferred to Bristol Myers Squibb. The relevant protection is expected to include composition-of-matter patents, pharmaceutical compositions, dosing regimens and therapeutic uses.
Because the drug is not FDA-approved, it has no Orange Book-listed patents. Patent term, terminal disclaimers, patent-term adjustment and any future pediatric exclusivity cannot be confirmed as a single market-exclusivity date without the approved product, applicable patent records and the final FDA listing.
Which intellectual-property barriers matter most?
The composition-of-matter patent is generally the strongest protection for a small-molecule product because it can cover the active compound across indications and formulations. Secondary patents may cover:
- Iberdomide hydrochloride or other solid forms
- Pharmaceutical compositions
- Specific dose schedules
- Combination treatment with dexamethasone or other anti-myeloma agents
- Treatment of patients refractory to lenalidomide or pomalidomide
- Manufacturing processes and intermediates
Secondary patents can delay or complicate generic entry, but their strength depends on claim scope, prosecution history, validity challenges and the availability of non-infringing alternatives.
When could generic iberdomide enter the market?
No generic-entry date can be stated with confidence before FDA approval and identification of the patents listed for the approved product. A conventional generic would typically require an Abbreviated New Drug Application and could challenge listed patents through Paragraph IV certification.
Potential launch pathways include:
- A Paragraph IV challenge to composition or formulation patents.
- A launch after expiration of the relevant patent estate.
- A settlement allowing an agreed entry date.
- A limited launch after a court ruling or patent invalidity finding.
- A later generic after exclusivity expires even if secondary patents remain.
Because iberdomide is a small molecule, biosimilar risk does not apply. The relevant competitive threat is generic substitution, not biosimilar interchangeability.
Which companies are challenging iberdomide commercially?
No commercial generic company can currently launch iberdomide because the product is not approved. The competitive field instead includes companies developing treatments for the same multiple myeloma population.
| Company |
Competing product or platform |
Competitive relevance |
| Johnson & Johnson and Legend Biotech |
Carvykti |
BCMA-directed CAR-T therapy |
| Bristol Myers Squibb and bluebird bio |
Abecma |
BCMA-directed CAR-T therapy |
| Johnson & Johnson and Genmab |
Tecvayli and Talvey |
Bispecific antibody therapies |
| Pfizer |
Elrexfio |
BCMA-directed bispecific therapy |
| Sanofi |
Sarclisa |
Anti-CD38 antibody platform |
| Generic manufacturers |
Lenalidomide and pomalidomide |
Low-cost background therapy |
| Other biotech companies |
CELMoDs, bispecifics and cellular therapies |
Pipeline competition |
The key distinction is that iberdomide could offer outpatient oral administration, while many competitors require infusion, injection, monitoring or specialized treatment infrastructure.
What licensing deals and corporate transactions affect iberdomide?
Iberdomide entered Bristol Myers Squibb’s portfolio through the Celgene acquisition. It was not obtained through a standalone external licensing transaction publicly associated with the molecule.
The Celgene transaction gave BMS access to a broader hematology portfolio, including Revlimid, Pomalyst, Abraxane and multiple development programs. Iberdomide’s financial value must therefore be assessed within BMS’s integrated hematology strategy rather than as an independently licensed asset.
What litigation or settlement risk affects iberdomide?
No major Paragraph IV litigation or generic settlement can arise before an FDA-approved iberdomide product has listed patents and an ANDA filer challenges those patents. The principal near-term legal risks are development-related:
- Patent validity challenges by future generic applicants
- Obviousness attacks against secondary formulation or method-of-use claims
- Enablement and written-description challenges
- Patent-term disputes
- Inventorship or ownership disputes
- Freedom-to-operate issues involving CELMoD chemistry or manufacturing
The likelihood of litigation would increase after approval and publication of Orange Book patent listings.
How strong is the commercial position of iberdomide?
Iberdomide has a potentially strong scientific position in a narrow but important treatment segment. Its advantages are oral dosing, a differentiated mechanism within the CELMoD class and possible activity after resistance to earlier immunomodulatory drugs.
Its weaknesses are equally material:
- No approved indication
- No current revenue
- Dependence on Phase 3 success
- Heavy competition in relapsed multiple myeloma
- Possible overlap with BMS’s mezigdomide program
- Shorter treatment duration in late-line disease
- Reimbursement pressure from high-cost cellular and antibody therapies
The product’s commercial ceiling is highest if BMS demonstrates benefit in earlier relapsed disease and develops durable combination regimens. A label limited to heavily pretreated patients would create a smaller, more volatile revenue stream.
Key Takeaways
- Iberdomide hydrochloride is an investigational oral CELMoD owned by Bristol Myers Squibb.
- It has no FDA approval, Orange Book listing or product revenue.
- The main target is relapsed or refractory multiple myeloma, particularly disease resistant to lenalidomide and pomalidomide.
- Commercial value depends on Phase 3 efficacy, safety, treatment duration and differentiation from bispecific antibodies and CAR-T therapies.
- No reliable generic-entry date exists before approval and identification of listed patents.
- Biosimilar competition is irrelevant because iberdomide is a small molecule.
- The strongest financial scenario requires expansion beyond late-line disease into earlier relapsed treatment and combination use.
- The immediate financial trajectory is continued R&D spending with no offsetting product revenue.
FAQs
Is iberdomide hydrochloride approved by the FDA?
No. Iberdomide remains an investigational drug and has no FDA-approved product label based on publicly available information through June 2024.
Does iberdomide have commercial sales?
No. Bristol Myers Squibb does not report iberdomide product revenue because the drug has not reached the market.
Is iberdomide a generic version of Revlimid?
No. Iberdomide is a new investigational CELMoD compound. Revlimid is the brand name for lenalidomide, an older immunomodulatory drug that now faces generic competition.
Could iberdomide replace pomalidomide?
Potentially in selected relapsed or refractory patients, but replacement depends on comparative clinical evidence, regulatory labeling, reimbursement and physician adoption.
Does iberdomide face biosimilar competition?
No. Iberdomide is a small-molecule drug. Any post-approval competition would generally come through generic-drug pathways rather than biosimilar applications.
References
-
Bristol Myers Squibb. (2019). Bristol-Myers Squibb completes acquisition of Celgene, creating a leading biopharma company. https://news.bms.com
-
Bristol Myers Squibb. (2023). Annual report 2023. https://www.bms.com/investors/annual-reports.html
-
ClinicalTrials.gov. (n.d.). Iberdomide clinical studies in multiple myeloma. U.S. National Library of Medicine. https://clinicaltrials.gov
-
U.S. Food and Drug Administration. (n.d.). Orange Book: Approved drug products with therapeutic equivalence evaluations. https://www.accessdata.fda.gov/scripts/cder/ob/
-
International Myeloma Foundation. (2024). Multiple myeloma treatment landscape and emerging therapies. https://www.myeloma.org
